Cytosorbents (NASDAQ:CTSO) Now Covered by StockNews.com

Investment analysts at StockNews.com assumed coverage on shares of Cytosorbents (NASDAQ:CTSO) in a report released on Friday. The firm set a “hold” rating on the medical research company’s stock.

Separately, HC Wainwright reiterated a “neutral” rating and issued a $1.00 price target on shares of Cytosorbents in a report on Monday, November 11th.

Cytosorbents Trading Up 4.0 %

NASDAQ CTSO opened at $0.92 on Friday. The company has a current ratio of 1.97, a quick ratio of 1.58 and a debt-to-equity ratio of 1.06. The company’s fifty day simple moving average is $0.95 and its 200-day simple moving average is $1.01. The stock has a market cap of $50.03 million, a P/E ratio of -2.54 and a beta of 0.57. Cytosorbents has a 52 week low of $0.70 and a 52 week high of $1.92.

Institutional Trading of Cytosorbents

Institutional investors have recently made changes to their positions in the stock. CM Management LLC boosted its stake in shares of Cytosorbents by 3.0% during the 2nd quarter. CM Management LLC now owns 850,000 shares of the medical research company’s stock worth $598,000 after acquiring an additional 25,000 shares in the last quarter. Geode Capital Management LLC increased its position in Cytosorbents by 7.5% during the third quarter. Geode Capital Management LLC now owns 467,058 shares of the medical research company’s stock worth $701,000 after acquiring an additional 32,415 shares during the period. Atomi Financial Group Inc. acquired a new position in Cytosorbents during the 3rd quarter valued at $51,000. Finally, Sargent Investment Group LLC boosted its holdings in Cytosorbents by 4.9% in the 2nd quarter. Sargent Investment Group LLC now owns 1,433,500 shares of the medical research company’s stock valued at $1,008,000 after purchasing an additional 67,181 shares during the period. 32.87% of the stock is currently owned by institutional investors and hedge funds.

Cytosorbents Company Profile

Cytosorbents Corporation engages in the research, development, and commercialization of medical devices with its blood purification technology platform incorporating a proprietary adsorbent and porous polymer technology in the United States, Germany, and internationally. Its flagship product is CytoSorb, an extracorporeal cytokine adsorber for adjunctive therapy in the treatment of sepsis, adjunctive therapy in other critical care applications, prevention, and treatment of perioperative complications, and maintaining or enhancing the quality of solid organs harvested from donors for organ transplant; and offers VetResQ, a device for adjunctive therapy in the treatment of sepsis, pancreatitis, and other critical illnesses in animals.